A Phase 2 interventional study of Placebo and MORF-057 in Inflammatory Bowel Diseases and Crohn's Disease, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). Recruiting at 224 sites in 28 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Crohn Disease by Eli Lilly and Company — 6 open to participants now, 7 under way, 4 of them phase 3. Crohn Disease · Eli Lilly and Company.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 7th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 10 studies in Crohn Disease by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Belgium and 19 more countries
Ages 18–70
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–17
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 385 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 171 across the 10 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), one of the names counted as Eli Lilly and Company. Under that name alone:
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
2 of the studies in Crohn Disease by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07483099Eli Lilly and CompanyA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | 2027-06 |
| NCT07483073Eli Lilly and CompanyA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of induction therapy with 3 active dose regimens of MORF-057 versus matching placebo in adult study participants with moderately to severely active CD. After completion of the 14-week Induction Period, all participants will receive open-label MORF-057 during the 38-week Maintenance Period. All participants who complete the full 52-week Treatment Period will also have the opportunity to continue treatment in a 52-week Long-Term Extension.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
This study's planned enrollment of 385 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company.
Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded MORF-057 Dosing Regimen 1 for Induction Period and open-label MORF-057 for Maintenance Period
Drug: MORF-057
Blinded MORF-057 Dosing Regimen 2 for Induction Period and open-label MORF-057 for Maintenance Period
Drug: MORF-057
Blinded matching placebo for Induction Period and open-label MORF-057 for Maintenance Period
Drug: Placebo · Drug: MORF-057
Blinded MORF-057 Dosing Regimen 1 for Induction Period and open-label MORF-057 for Maintenance Period
Drug: MORF-057
Blinded MORF-057 Dosing Regimen 2 for Induction Period and open-label MORF-057 for Maintenance Period
Drug: MORF-057
Blinded matching placebo for Induction Period and open-label MORF-057 for Maintenance Period
Drug: Placebo · Drug: MORF-057
Matching placebo (identical appearance to MORF-057) administered orally.
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Also known as: zotemtegrast
Proportion of participants with endoscopic response at Week 14 as determined using the Simple Endoscopic Score-CD (SES-CD)
The SES-CD is an endoscopic scoring system for evaluating CD activity. Endoscopic response is defined as an SES-CD decrease from baseline of ≥50%
Time frame: Baseline to Week 14
Proportion of participants with clinical response at Week 14 as determined using the Crohn's Disease Activity Index (CDAI)
The CDAI is a composite of subscores for clinical and laboratory findings, and patient-reported CD symptoms. Clinical response is defined as a reduction from baseline CDAI score by ≥100 points or a CDAI score of \<150 points.
Time frame: Baseline to Week 14
Proportion of participants with clinical remission at Week 14 as determined using the CDAI.
The CDAI is a composite of subscores for clinical and laboratory findings, and patient-reported CD symptoms. Clinical remission is defined as a CDAI score of \<150 points.
Time frame: Baseline to Week 14
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 224 sites across 28 countries. Choose a country and city above to see the rest.
Started Jul 2024 (actual). Primary completion is estimated for Sep 2028, 50 months after the start.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 50 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MORF-057
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) →